Business
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug
About this update from Cosmos Health Inc.
[{"type":"image","alt":"Cosmos Health Inc.","displaySize":"","headline":null,"caption":"Cosmos Health Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zU4V54zW1TjV8qFkho7Qmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a","width":300,"height":157}},"lazy":false},{"type":"text","content":"CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development.","length":414,"tagName":"p"},{"type":"text","content":"Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmune diseases. Athos has developed AthosOmics.AI, a proprietary AI-driven drug development platform that resulted in the discovery of ATH-063, an AI-derived small molecule currently being evaluated in a Phase 2 clinical trial in ulcerative colitis patients.","length":546,"tagName":"p"},{"type":"text","content":"He began his academic career at Harvard Medical School as an Assistant Professor of Microbiology & Immunology and later became a tenured Associate Professor of Medicine at the UCLA School of Medicine. At UCLA, he founded and directed the UCLA Center for Systems Biomedicine, funded by the Eli & Edythe Broad Foundation.","length":327,"tagName":"p"},{"type":"text","content":"Throughout his career, Dr. Iliopoulos has received multiple national and international awards from institutions including the National Institutes of Health (NIH), the American Association for Cancer Research, the Sidney Kimmel Foundation, and the Leona & Harry Helmsley Foundation for identifying novel genes and advancing drug development for autoimmune diseases and cancer. He has ...